Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naseema Gangat

Showing results (1-10 of 410) with videos related to

Pageof 41
Sort By:
Scandinavian Journal of Infectious Diseases|March 17, 2007
Cerebral abscesses complicating tularemia meningitisNaseema Gangat
Journal of General Internal Medicine|August 22, 2006
The PRIME curriculum clinical research training during residency: response to Kohlwes et alNaseema Gangat
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 19, 2023
Sodium-glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematologyNaseema Gangat, Ayalew Tefferi
Blood Cancer Journal|May 7, 2025
Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and consNaseema Gangat, Ayalew Tefferi
Blood Cancer Journal|April 26, 2022
To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemiaNaseema Gangat, Ayalew Tefferi
American Journal of Hematology|October 21, 2025
The Hemojuvelin-Hepcidin Axis as a Target for the Treatment of Anemia or Conversely PolycythemiaNaseema Gangat, Ayalew Tefferi
American Journal of Hematology|May 29, 2025
CPX-351 (Vyxeos) in Acute Myeloid Leukemia: Time to Move on?Naseema Gangat, Ayalew Tefferi
American Journal of Hematology|March 8, 2025
Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic SyndromesNaseema Gangat, Ayalew Tefferi
Expert Opinion on Therapeutic Targets|April 12, 2021
Myelofibrosis: challenges for preclinical models and emerging therapeutic targetsErika Morsia, Naseema Gangat
British Journal of Haematology|March 21, 2020
Myelofibrosis biology and contemporary managementNaseema Gangat, Ayalew Tefferi
Pageof 41

Showing results (1-10 of 410) with videos related to

Sort By:
Pageof 41
Scandinavian Journal of Infectious Diseases|March 17, 2007
Cerebral abscesses complicating tularemia meningitisNaseema Gangat
Journal of General Internal Medicine|August 22, 2006
The PRIME curriculum clinical research training during residency: response to Kohlwes et alNaseema Gangat
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 19, 2023
Sodium-glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematologyNaseema Gangat, Ayalew Tefferi
Blood Cancer Journal|May 7, 2025
Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and consNaseema Gangat, Ayalew Tefferi
Blood Cancer Journal|April 26, 2022
To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemiaNaseema Gangat, Ayalew Tefferi
American Journal of Hematology|October 21, 2025
The Hemojuvelin-Hepcidin Axis as a Target for the Treatment of Anemia or Conversely PolycythemiaNaseema Gangat, Ayalew Tefferi
American Journal of Hematology|May 29, 2025
CPX-351 (Vyxeos) in Acute Myeloid Leukemia: Time to Move on?Naseema Gangat, Ayalew Tefferi
American Journal of Hematology|March 8, 2025
Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic SyndromesNaseema Gangat, Ayalew Tefferi
Expert Opinion on Therapeutic Targets|April 12, 2021
Myelofibrosis: challenges for preclinical models and emerging therapeutic targetsErika Morsia, Naseema Gangat
British Journal of Haematology|March 21, 2020
Myelofibrosis biology and contemporary managementNaseema Gangat, Ayalew Tefferi
Pageof 41